MedStar Diabetes Pathway Chart Reviews (MDP phase 2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03442595|
Recruitment Status : Active, not recruiting
First Posted : February 22, 2018
Last Update Posted : February 22, 2018
|Condition or disease||Intervention/treatment|
|Type2 Diabetes Mellitus||Other: Intensive diabetes education and medication management|
The MedStar Diabetes Pathway (MDP) early pilot program has generated evidence that an innovative technology-enabled "Boot Camp" approach to the delivery of diabetes survival skills education and medication management has a significant impact on glycemic control and healthcare utilization measures. The MDP is a 12 week Diabetes "Boot Camp" technology-enabled intervention which will offer learner-centered survival skills self-management education (DSSE) and algorithm-driven diabetes medications (DM) titration by Endocrinologist-supervised Certified Diabetes Educators (CDE), NPs and PharmDs. The program has been offered at 5 MedStar Medical Group (MMG) Primary Care Practices from November 2014 to February 2016 to high risk adults with uncontrolled type 2 diabetes who have a hemoglobin A1C (A1C) level -a marker of average blood glucose (BG) levels in the 2-3 months prior to the time the test is done- which is at or above 9% - considered to be poor control, and 1 or more additional risk factors for poor health outcomes. The program has been well received by MedStar Primary Care Providers and their diabetes patients. Patients that participated in the MDP achieved significantly higher A1C reduction and decreased risk risk for acute care utilization then matched controls that received standard of care. The pilot evidence demonstrated a significant impact on glycemic control and healthcare utilization measures as the result of a concise, focused DM education and medication management intervention. Building on the success of the MDP Phase 1.0 pilot, the next steps in expanding the program will be as follows:
- Transition of the Pathway from early feasibility pilot to the next phase as an expanded pilot program integrated within the MedStar Health System care delivery network and built upon a sustainable infrastructure across early adopter MMG practice sites.
- Expand recruitment to include high risk patients with uncontrolled type 2 diabetes, including those with a new diagnosis and A1C >9%, who have MedStar Emergency Department and/or Inpatient encounters
- Spread to additional targeted MedStar Primary Care Practices and/or to MedStar Managed Care Plan participants.
Chart reviews and data collection during the expansion phase will be essential to guide the process and allow rapid cycle adjustments to maximize the impact of the program and utilization of resources for the benefit of our patients.
|Study Type :||Observational|
|Actual Enrollment :||400 participants|
|Official Title:||Expanded MedStar Diabetes Pathway Ongoing Chart Review Protocol|
|Actual Study Start Date :||July 1, 2016|
|Estimated Primary Completion Date :||June 30, 2018|
|Estimated Study Completion Date :||December 31, 2018|
patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
Other: Intensive diabetes education and medication management
Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
- A1C [ Time Frame: 12-16 weeks ]Change in Hemoglobin A1C from baseline
- ED utilization [ Time Frame: 4 weeks and 12 weeks ]Number of visits to the ED from baseline
- Hospitalizations [ Time Frame: 4 weeks and 12 weeks ]Numbers of hospitalizations from baseline
- ED and hospitalizations [ Time Frame: 4 weeks and 12 weeks ]Number of ED visits and hospitalizations combined from baseline
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03442595
|Principal Investigator:||Michelle F Magee, MD||Medstar Health Research Institute|